Peter Diamandis addresses healthspan progress, opportunities and challenges ahead of Hevolution’s Global Healthspan Summit.

a16z’s Jorge Conde says uncovering ‘unexpected causal relationships’ in biology could define the future of healthspan.

Drug emerged from research into the cardiac protection mechanisms of hibernating ground squirrels; clinical trial expected in 2026.

Metabolic health companies join forces as CGM giant pours $75m into smart ring leader, at a valuation of more than $5bn.

MetaShape’s PNP inhibitor technology aims to restore NAD+ levels to combat LDL cholesterol, cognitive decline and neurodegeneration.